Rivaroxaban for acute coronary syndrome: final appraisal determination
National Institute for Health and Care Excellence
In DRAFTguidance, NICE supports use of rivaroxaban, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in people who have had an ACS with elevated cardiac biomarkers. Bleeding risk should be assessed before treatment is started.
Journal of Clinical Oncology
An evidence update which included a review of 53 publications, found that the 2014 recommendations are consistent with the 2013 recommendations.
Patient Safety Alert (stage one): Harm from using Low Molecular Weight Heparins when contraindicated
NHS England
Consideration of contraindications is a prominent feature of available local and national guidance for prescribing and administering LMWHs. This stage one Patient Safety Alert aims to reinforce the need for reliable systems to ensure that this always occurs.
Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
Circulation
A US report found approx 5.9% of end-stage renal disease patients with AF are started on dabigatran or rivaroxaban despite the drugs being contraindicated in these patients; both were associated with a higher risk of hospitalisation or death from bleeding compared to warfarin.
The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service.
Further details on this service can be found at: